Adempas (riociguat) — Medica
Chronic thromboembolic pulmonary hypertension (CTEPH)
Initial criteria
- For CTEPH: prescribed by or in consultation with a pulmonologist or a cardiologist
- For PAH initial therapy: diagnosis of WHO Group 1 pulmonary arterial hypertension (PAH); AND patient has had a right heart catheterization [documentation required]; AND results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH; AND medication is prescribed by or in consultation with a cardiologist or a pulmonologist
Reauthorization criteria
- For CTEPH: prescribed by or in consultation with a pulmonologist or a cardiologist
- For PAH if patient is currently receiving Adempas: diagnosis of WHO Group 1 PAH; AND patient has had a right heart catheterization; AND results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH; AND medication is prescribed by or in consultation with a cardiologist or a pulmonologist
Approval duration
1 year